Overview
Grant Avenue Capital has recapitalized CREO Inc.
Significance
The life sciences consulting industry is witnessing a dynamic shift as it adapts to emerging trends. With advancements in biotechnology, precision medicine, and data analytics, consulting firms are playing a pivotal role in guiding pharmaceutical, biotech, and healthcare companies towards innovation and market success. The complex regulatory landscape, coupled with the challenges of global expansion and pricing strategies, underscores the demand for specialized consulting expertise. A growing emphasis on patient-centricity, diversity in clinical trials, and environmental sustainability are shaping the industry’s trajectory. Life sciences consulting is not only a catalyst for change but also a key driver in advancing healthcare and pharmaceutical solutions reshaping the future.
Founded in 2015, CREO Inc. (“CREO”) is an award-winning provider of strategy, M&A, digital transformation, cyber security, IT quality and regulatory compliance consulting services to life sciences and healthcare organizations. CREO boasts an impressive history of delivering business results and expanding its customer base, exemplified by its consistent inclusion in the Inc. 5000 list of America’s fastest-growing private companies for the last four years and its recurrent recognition on the Triangle Business Journal’s Fast 50 list of rapidly growing companies in the Triangle region. CREO’s impressive capabilities and market leadership position made it the ideal strategic partner for Grant Avenue Capital to enhance the build out of its life sciences consulting platform.
Crosstree’s Role
Crosstree’s comprehensive knowledge of the life sciences consulting industry assisted Grant Avenue in evaluating CREO as the optimal partner through:
- Assessing the potential of strategic growth opportunities for CREO
- Developed a market information strategy to underwrite the recapitalization of CREO
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Versiti Acquired Quantigen to Further Expand Clinical Trial Expertise and Service Offering
Access Medical Labs Allies with Grupo Diagnostico Aries to Expand Diagnostic Lab Capabilities into North America
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
